FreeSTyle LibRe and hospitAl Admissions, morTality and qUality of Life in High Risk Type 2 diabeteS Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes
- Sponsor
- University of Leeds
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Mortality at 2 years
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
This study aims to investigate the utility of a combination of structured nurse led intervention and the use of Freestyle libre in adults with type 2 diabetes who have suffered an episode of severe hypoglycaemia in terms of mortality, unscheduled healthcare contacts and quality of life.
Detailed Description
It is increasingly recognised that hypoglycaemia carries risk to individuals with all forms of diabetes. Research has shown high rate of mortality in those with type 2 diabetes following an episode of severe hypoglycaemia and a previous pilot trial conducted in the UK suggested that this could be improved by a structured nurse led intervention aimed at modifying glycemic therapy to avoid hypoglycaemia, instigating regular blood glucose monitoring and providing education to participants on common triggers for hypoglycaemia and how to avoid them. In this trial, the investigators will randomise individuals with type 2 diabetes who have suffered an episode of severe hypoglycaemia requiring emergency service call out to two arms. One arm will receive standard of care/treatment as usual and the other will receive a structured nurse led intervention as well as the use of a flash glucose monitoring system, Freestyle libre. Active participation in the trial for both arms will be a total of twelve months (with the main intervention months 0-6.) Participants electronic records will be analysed for death and unscheduled healthcare contacts for a total of two years after recruitment. The primary outcome measure is mortality between groups. Secondary outcomes include the use of estimated HbA1c (a variable produced by the freestyle libre device) compared to laboratory HbA1c, quality of life measures, effects on glycemic control and the number of unscheduled healthcare contacts.
Investigators
Ramzi Ajjan
Professor of metabolic medicine
University of Leeds
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Mortality at 2 years
Time Frame: 2 years
Rates of death between groups at 2 years
Secondary Outcomes
- All-cause mortality at 1 year(12 months)
- Cardiovascular mortality at 2 years(2 years)
- Cardiovascular mortality at 1 year(1 year)
- Change from baseline in HbA1c(6 months)
- Scores from treatment satisfaction scale (DTSQc)(Tested at 0 and 6 months)
- Number of unscheduled healthcare contacts(2 years after randomisation)
- Comparison between estimated HbA1c and laboratory HbA1c(6 months)
- Scores from Diabetes distress scale(Tested at 0 and 6 months)
- Scores from GOLD score(Tested at 0 and 6 months)
- Scores from diabetes quality of life scale (DQOL)(Tested at 0 and 6 months)